Roth Capital reiterated a Buy rating on Spark Therapeutics (NASDAQ: ONCE), and raised the price target to $90.00 (from $71.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst PT Change

Chardan Capital Says to Buy Spark Therapeutics (ONCE) Peers Following SPK-RPE65 Results (AAVL) (VBLT)October 5, 2015 10:34 AM Cowen Remains Bullish on Spark Therapeutics (ONCE) Following Top-Line SPK-RPE65 Results October 5, 2015 10:14 AM Pre-Open Stock Movers 10/05: (ONCE) (FOLD) (TWTR) Higher; (APP) (FEYE) (VRX) Lower (more...)October 5, 2015 9:24 AM Spark Therapeutics (ONCE) Announces SPK-RPE65 Phase 3 Met Primary EndpointOctober 5, 2015 6:23 AM Spark Therapeutics Announces Positive Top-line Results From Pivotal Phase 3 Trial of SPK-RPE65 for Genetic Blinding ConditionsOctober 5, 2015 6:00 AM